COO Stock Analysis: The Cooper Companies | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 10.301m USD | 12M Return: -21.3% | US2166485019 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 136M
EPS Trend: 99.7%
Qual. Beats: 6
Rev. Trend: 99.4%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Cooper Companies, Inc. (NASDAQ: COO) is a U.S.-based, large-cap healthcare supplies company headquartered in San Ramon, California, founded in 1958 and publicly traded since 1983. It operates through two segments: CooperVision, which designs, manufactures, and markets a range of contact lenses-including spherical, toric, and multifocal products addressing conditions such as astigmatism, presbyopia, and myopia-and CooperSurgical, which serves the family and womens healthcare market with products and services spanning fertility, medical devices, contraception, and cryostorage (including cord blood and tissue storage). Notable offerings within CooperSurgical include the Paragard hormone-free intrauterine device, fertility consumables and equipment, donor gamete services, and genomic/genetic testing. The company sells through a diversified channel network that includes distributors, group purchasing organizations, eye care and health care professionals, independent practices, corporate retailers, hospitals and clinics, and authorized resellers.
The contact lens business follows a recurring-revenue model driven by the disposable replacement cycle, and the global market for soft contact lenses is an oligopoly dominated by a small group of manufacturers. CooperSurgical operates in the womens health and fertility care space, an area supported by long-term demographic trends such as rising maternal age and growing demand for assisted reproductive services.
- CooperVision myopia management lens adoption drives segment growth
- CooperSurgical fertility and Paragard revenue offsets lens softness
- Strong dollar FX headwinds pressure international operating margins
| Net Income: 570.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -2.61 > 1.0 |
| NWC/Revenue: 9.79% < 20% (prev 27.87%; Δ -18.08% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.03b > Net Income 570.3m |
| Net Debt (2.39b) to EBITDA (910.2m): 2.63 < 3 |
| Current Ratio: 1.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (193.4m) vs 12m ago -3.59% < -2% |
| Gross Margin: 63.64% > 18% (prev 66.96%; Δ -3.32% > 0.5%) |
| Asset Turnover: 33.83% > 50% (prev 32.69%; Δ 1.14% > 0%) |
| Interest Coverage Ratio: 5.56 > 6 (EBIT TTM 526.3m / Interest Expense TTM 94.6m) |
| A: 0.03 (Total Current Assets 2.28b - Total Current Liabilities 1.87b) / Total Assets 12.7b |
| B: 0.64 (Retained Earnings 8.13b / Total Assets 12.7b) |
| C: 0.04 (EBIT TTM 526.3m / Avg Total Assets 12.5b) |
| D: 1.92 (Book Value of Equity 8.33b / Total Liabilities 4.34b) |
| Altman-Z'' = 4.60 = AA |
| DSRI: 0.95 (Receivables 788.9m/792.3m, Revenue 4.24b/4.05b) |
| GMI: 1.05 (GM 66.96% / 63.64%) |
| AQI: 0.98 (AQ_t 0.65 / AQ_t-1 0.67) |
| SGI: 1.05 (Revenue 4.24b / 4.05b) |
| TATA: -0.04 (NI 570.3m - CFO 1.03b) / TA 12.7b) |
| Beneish M = -3.00 (Cap -4..+1) = AA |
As of September 13, 2026, the stock is trading at USD 53.91 with a total of 6,438,834 shares traded. Over the past week, the price has changed by -23.68%, over one month by -29.82%, over three months by -20.15% and over the past year by -21.25%.
Current recommended Stop Loss: 50.70 (which is 6% or 1.2 ATR below the current price).
The Cooper Companies has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy COO.
- StrongBuy: 9
- Buy: 2
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 81.5 | 51.2% |
P/E Trailing = 21.8427
P/E Forward = 12.9534
P/S = 2.4346
P/B = 1.4894
P/EG = 0.6025
Revenue TTM = 4.24b USD
EBIT TTM = 526.3m USD
EBITDA TTM = 910.2m USD
Long Term Debt = 2.46b USD (from longTermDebt, last fiscal year)
Short Term Debt = 628.1m USD (from shortTermDebt, last quarter)
Debt = 2.55b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.50m
Net Debt = 2.39b USD (calculated: Debt 2.55b - CCE 154.7m)
Enterprise Value = 12.7b USD (10.3b + Debt 2.55b - CCE 154.7m)
Interest Coverage Ratio = 5.56 (Ebit TTM 526.3m / Interest Expense TTM 94.6m)
EV/FCF = 140.1x (Enterprise Value 12.7b / FCF TTM 90.6m)
FCF Yield = 0.71% (FCF TTM 90.6m / Enterprise Value 12.7b)
FCF Margin = 2.14% (FCF TTM 90.6m / Revenue TTM 4.24b)
Net Margin = 13.46% (Net Income TTM 570.3m / Revenue TTM 4.24b)
Gross Margin = 63.64% ((Revenue TTM 4.24b - Cost of Revenue TTM 1.54b) / Revenue TTM)
Gross Margin QoQ = 62.36% (prev 68.00%)
Tobins Q-Ratio = 1.00 (Enterprise Value 12.7b / Total Assets 12.7b)
Interest Expense / Debt = 3.71% (Interest Expense 94.6m / Debt 2.55b)
Taxrate = 33.82% (191.6m / 566.5m)
NOPAT = 348.3m (EBIT 526.3m * (1 - 33.82%))
Current Ratio = 1.22 (Total Current Assets 2.28b / Total Current Liabilities 1.87b)
Debt / Equity = 0.31 (Debt 2.55b / totalStockholderEquity, last quarter 8.33b)
Debt / EBITDA = 2.63 (Net Debt 2.39b / EBITDA 910.2m)
Debt / FCF = 26.40 (Net Debt 2.39b / FCF TTM 90.6m)
Total Stockholder Equity = 8.29b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.55% (Net Income 570.3m / Total Assets 12.7b)
RoE = 6.88% (Net Income TTM 570.3m / Total Stockholder Equity 8.29b)
RoCE = 4.90% (EBIT 526.3m / Capital Employed (Equity 8.29b + L.T.Debt 2.46b))
RoIC = 3.09% (NOPAT 348.3m / Invested Capital 11.3b)
WACC = 6.24% (E(10.3b)/V(12.8b) * Re(7.17%) + D(2.55b)/V(12.8b) * Rd(3.71%) * (1-Tc(0.34)))
Discount Rate = 7.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.94 | Cagr: -1.59%
[DCF] Terminal Value 73.10% ; FCFF base≈219.1m ; Y1≈192.2m ; Y5≈155.3m
[DCF] Fair Price = 0.53 (EV 2.49b - Net Debt 2.39b = Equity 100.0m / Shares 190.2m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 99.73 | EPS CAGR: 14.23% | SUE: 1.19 | # QB: 6
Revenue Correlation: 99.39 | Revenue CAGR: 6.26% | SUE: -2.47 | # QB: -1
EPS current Year (2026-10-31): EPS=4.63 | Chg30d=-0.06% | Revisions=-25% | GrowthEPS=+12.3% | GrowthRev=+5.2%
EPS next Year (2027-10-31): EPS=5.00 | Chg30d=-0.17% | Revisions=-25% | GrowthEPS=+8.0% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -40% (up=0, down=2)